-

Shareholder Alert: Robbins LLP is Investigating CytoDyn Inc. (CYDY) on Behalf of Shareholders

SAN DIEGO & VANCOUVER, Wash.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating CytoDyn Inc. (OTC: CYDY) on behalf of shareholders to determine whether certain CytoDyn officers and directors violated the Securities Exchange Act of 1934 and breached their fiduciary duties to the Company.

If you suffered a loss due to CytoDyn Inc.'s misconduct, click here.

CytoDyn Inc. (CYDY) Misled Shareholders About the Viability of its Drug for the Treatment of COVID-19

CytoDyn is a biotech company that - prior to the COVID-19 pandemic - was focusing on the development and commercialization of the drug "Leronlimab" for the treatment of patients with HIV. Since the beginning of the COVID-19 pandemic, CytoDyn has aggressively touted Leronlimab as a treatment for COVID-19, including that it had sought emergency use authorization ("EUA") from the U.S. Federal Drug Administration ("FDA") and planned to move forward with Operation Warp Speed. This, in turn, caused CytoDyn's stock price to skyrocket. Having traded at less than $1 per share throughout 2019, CytoDyn's stock reached its peak on June 30, 2020, trading at over $10 per share. While the stock price was artificially inflated, insiders dumped millions of shares for almost $26 million.

Thereafter, the Company's scheme began to unravel. On August 26, 2020, The Wall Street Journal reported that CytoDyn was not being considered for Operation Warp Speed. On September 16, 2020, CytoDyn's CEO admitted the Company had not actually made the request for EUA from the FDA. Beginning on March 5, 2021, the Company revealed that the primary endpoints of its Phase IIb/III data on Leronlimab was not statistically significant. On this news, CytoDyn's stock plummeted over several trading days, to close at just $2.35 on March 9. 2021.

CytoDyn Inc. (CYDY) Shareholders Have Options

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against CytoDyn Inc. settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Industry:

Robbins LLP

OTCBB:CYDY
Release Versions
English
$Cashtags
$CYDY
Hashtags
#ShareholderRights
#Shareholders
#StockMarket
#Stocks

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

CPNG Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Against Coupang, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Coupang, Inc. (NYSE: CPNG) securities between April 6, 2025 and December 16, 2025. Coupang describes itself as one of the fastest-growing technology and commerce companies in the world, providing retail, restaurant delivery, video streaming, and fintech services to customers around the world under brands that include Coupang, Coupang Eats, Cou...

Did You Lose Money in SFM? Stockholders Who Incurred Significant Financial Loss in Sprouts Farmers Market, Inc. Should Contact Robbins LLP to Learn About Leading the SFM Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP: Company: Sprouts Farmers Market, Inc. (NASDAQ: SFM) is a specialty grocery store chain that operates in the U.S. What is the class period? June 4, 2025 - October 29, 2025. What is the case about? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Sprouts Farmers Market, Inc. during the class period because the Company allegedly misled investors regarding its growth potential. For...

MCTA Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Securities Class Action Against Charming Medical, Limited

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Charming Medical, Limited (NASDAQ: MCTA) securities between October 10, 2025 and November 12, 2025. The Company claims to “enhance[] the quality of life from the inside out by integrating Traditional Chinese Medicine (TCM) wellness practices with modern technology.” For more information, submit a form, email attorney Aaron Dumas, Jr., or give...
Back to Newsroom